Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain

To examine the long‐term consequences of glycogen storage in the central nervous system (CNS) for classic infantile Pompe disease using enzyme replacement therapy.

• Publication year

  2018

• Venue

  Developmental Medicine & Child Neurology

• Publication date

  2018-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/dmcn.13740PMID 29573408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?

  2018cited by this paper
• Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up.

  2017cited by this paper
• Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy

  2016cited by this paper
• Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge

  2016cited by this paper
• Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.

  2015cited by this paper
• Premature pubarche in children with Pompe disease.

  2015cited by this paper
• Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.

  2015cited by this paper
• Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany.

  2015cited by this paper
• Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy

  2012cited by this paper
• Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

  2012cited by this paper
• Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: Long‐term follow‐up

  2012cited by this paper
• Acute progression of neuromuscular findings in infantile Pompe disease.

  2010cited by this paper
• CRIM-negative infantile Pompe disease: 42-month treatment outcome

  2010cited by this paper
• The Parieto-Frontal Integration Theory (P-FIT) of intelligence: Converging neuroimaging evidence

  2007cited by this paper
• Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

  2007cited by this paper
• Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

  2007cited by this paper
• Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease

  2006cited by this paper
• Brain Development in Infantile-Onset Pompe Disease Treated by Enzyme Replacement Therapy

  2006cited by this paper
• Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk

  2004cited by this paper
• Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

  2004cited by this paper
• Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.

  2004cited by this paper
• The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

  2003cited by this paper
• Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2

  2001cited by this paper
• Recombinant human α-glucosidase from rabbit milk in Pompe patients

  2000cited by this paper
• Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

  2000cited by this paper
• Pompe's disease: An inborn lysosomal disorder with storage of glycogen

  1973cited by this paper
• Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle.

  1973cited by this paper
• NERVOUS SYSTEM IN POMPE'S DISEASE: ULTRASTRUCTURE AND BIOCHEMISTRY

  1971cited by this paper
• POMPE'S DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE.

  1965cited by this paper

• Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease

  2026influential citation
• Latest Advancements in Treatment Options for Infantile-Onset Pompe Disease: A Comprehensive Narrative Review

  2025cites this paper
• Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice

  2025cites this paper
• AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.

  2025cites this paper
• Management of Pompe disease alongside and beyond ERT: a narrative review

  2025cites this paper
• Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease.

  2025cites this paper
• Exploring the use of the National Institutes of Health Toolbox Cognition Battery with children and adolescents with Pompe disease: Preliminary findings.

  2025cites this paper
• The lived experience of mothers caring for school-age children with Pompe disease: A qualitative study.

  2024cites this paper
• Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

  2024cites this paper
• Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.

  2024cites this paper
• Health-Related Quality of Life and Fatigue in Children with Pompe Disease

  2024cites this paper
• Failure of Autophagy in Pompe Disease

  2024cites this paper
• Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.

  2024cites this paper
• Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review

  2024cites this paper
• What can pediatricians learn from adult inherited metabolic diseases?

  2024cites this paper
• Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning

  2024cites this paper
• Navigating Pompe Disease Assessment: A Comprehensive Scoping Review

  2024cites this paper
• The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)

  2024cites this paper
• Pompe disease: Unmet needs and emerging therapies.

  2024cites this paper
• Lysosomal storage diseases.

  2024cites this paper
• Neurological glycogen storage diseases and emerging therapeutics

  2024cites this paper
• Brain glycogen build-up measured by magnetic resonance spectroscopy in classic infantile Pompe disease

  2024influential citation
• Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease

  2023cites this paper
• Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease.

  2023cites this paper
• Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort

  2023influential citation
• Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.

  2023cites this paper
• Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.

  2023cites this paper
• Clinical and neuroimaging review of monogenic cerebral small vessel disease from the prenatal to adolescent developmental stage

  2023cites this paper
• Innovating spinal muscular atrophy models in the therapeutic era

  2023cites this paper
• Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement

  2023cites this paper
• Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

  2023cites this paper
• A Comprehensive Update on Late-Onset Pompe Disease

  2023cites this paper
• Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants

  2023cites this paper
• AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice

  2023influential citation
• Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• Speech Disorders in Children With Pompe Disease: Articulation, Resonance, and Voice Measures.

  2023cites this paper
• [Research progress of nervous system damage in Pompe disease].

  2023cites this paper
• Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy

  2023cites this paper
• Gene Therapy Developments for Pompe Disease

  2022cites this paper
• Small fiber involvement is independent from clinical pain in late-onset Pompe disease

  2022cites this paper
• Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease

  2022cites this paper
• IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy

  2022cites this paper
• [Pulmonary phenotypes of inborn errors of metabolism].

  2022cites this paper
• Newborn screening for Pompe disease in Italy: Long-term results and future challenges

  2022cites this paper
• Prenatal Enzyme-Replacement Therapy.

  2022cites this paper
• Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease.

  2022cites this paper
• Diffusion tensor imaging of the brain in Pompe disease

  2022cites this paper
• Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management

  2022cites this paper
• Is the brain involved in patients with late‐onset Pompe disease?

  2021cites this paper
• A pilot study shows the positive effects of continuous airway pressure for treating hypernasal speech in children with infantile-onset Pompe disease

  2021cites this paper
• A novel PHKA1 mutation associating myopathy and cognitive impairment: Expanding the spectrum of phosphorylase kinase b (PhK) deficiency.

  2021cites this paper
• Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells

  2020cites this paper
• Cardiovascular disease in non-classic Pompe disease: A systematic review.

  2020cites this paper
• Skeletal muscle magnetic resonance imaging in Pompe disease

  2020cites this paper
• Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models

  2020influential citation
• Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects

  2020cites this paper
• Pompe Disease: New Developments in an Old Lysosomal Storage Disorder

  2020cites this paper
• Behavioral, social and school functioning in children with Pompe disease

  2020cites this paper
• Towards Central Nervous System Involvement in Adults with Hereditary Myopathies

  2020cites this paper
• White matter brain lesions in infantile-onset Pompe disease are not metabolically active using 18F-FDG PET/MR imaging.

  2020cites this paper
• Treating lysosomal storage disorders: What have we learnt?

  2020cites this paper
• Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins

  2020cites this paper
• Novel approaches to quantify CNS involvement in children with Pompe disease

  2020cites this paper
• Urodynamic and clinical studies in patients with late‐onset Pompe disease and lower urinary tract symptoms

  2020cites this paper
• Pompe disease: diagnostics and contemporary approaches of therapy

  2020cites this paper
• Advances in Diagnosis and Management of Pompe Disease

  2020cites this paper
• Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice

  2020cites this paper
• Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement

  2020influential citation
• Diagnosis and Care of Infants and Children with Pompe Disease

  2020cites this paper
• Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis

  2020cites this paper
• INTERMEDIATE UVEITIS WITH RETINAL DETACHMENT IN A PATIENT WITH POMPE DISEASE

  2020cites this paper
• Neurological Involvement in Glycogen Storage Disease Type IXa due to PHKA2 Mutation

  2020cites this paper
• An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

  2019cites this paper
• Clinical and Technological Dependence Characteristics on a Series of Brazilian Cases with Infantile Onset Pompe Disease in Enzyme Replacement Therapy

  2019cites this paper
• Severe distal muscle involvement and mild sensory neuropathy in a boy with infantile onset Pompe disease treated with enzyme replacement therapy for 6 years.

  2019cites this paper
• Improved efficacy of a next-generation ERT in murine Pompe disease.

  2019cites this paper
• Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease

  2019cites this paper
• Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.

  2019cites this paper
• Advancements in AAV-mediated Gene Therapy for Pompe Disease

  2019cites this paper
• Molecular Approaches for the Treatment of Pompe Disease

  2019cites this paper
• AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice

  2019cites this paper
• Progress and challenges of gene therapy for Pompe disease.

  2019cites this paper
• Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

  2019cites this paper
• Long-term outcome and unmet needs in infantile-onset Pompe disease.

  2019cites this paper
• Pompe disease: what are we missing?

  2019cites this paper
• Gene Therapy for Pompe Disease: The Time is now

  2019cites this paper
• Late-onset Pompe disease manifests in the brain

  2019cites this paper
• Human Mutation

  2019cites this paper
• White matter lesions in treated late onset Pompe disease are not different to matched controls.

  2019cites this paper
• Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale

  2019cites this paper
• Advances in imaging of brain abnormalities in neuromuscular disease

  2019cites this paper
• A Systematic Review of the Health Economics of Pompe Disease

  2019cites this paper
• Novel Pompe disease phenotype: a treatment‐related modified phenotype neglecting the brain

  2018influential citation
• microRNAs as biomarkers in Pompe disease

  2018cites this paper
• Pompe Disease: From Basic Science to Therapy

  2018cites this paper
• Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care.

  2018cites this paper
• Central nervous system involvement in late‐onset Pompe disease: clues from neuroimaging and neuropsychological analysis

  2018cites this paper